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Abstract
Objective: The aim of this review is to describe the historical development of research on cannabidiol. Method:  This review was carried out 
on reports drawn from Medline, Web of Science and SciELO. Discussion: After the elucidation of the chemical structure of cannabidiol in 
1963, the initial studies showed that cannabidiol was unable to mimic the effects of Cannabis. In the 1970’s the number of publications 
on cannabidiol reached a first peak, having the research focused mainly on the interaction with delta9-THC and its antiepileptic and 
sedative effects. The following two decades showed lower degree of interest, and the potential therapeutic properties of cannabidiol 
investigated were mainly the anxiolytic, antipsychotic and on motor diseases effects. The last five years have shown a remarkable increase 
in publications on cannabidiol mainly stimulated by the discovery of its anti-inflammatory, anti-oxidative and neuroprotective effects. These 
studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions, including Parkinson’s disease, 
Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer. Conclusion: 
In the last 45 years it has been possible to demonstrate that CBD has a wide range of pharmacological effects, many of which being of 
great therapeutic interest, but  still waiting to be confirmed by clinical trials. 
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Resumo
Objetivo: O objetivo desta revisão é descrever a evolução histórica das pesquisas sobre o canabidiol. Método: Esta revisão foi conduzida 
utilizando-se bases de dados eletrônicas (Medline, Web of Science e SciELO). Discussão: Após a elucidação de sua estrutura química, 
em 1963, os estudos iniciais do canabidiol demonstraram que ele não foi capaz de mimetizar os efeitos da maconha. Na década de 
70, o número de publicações sobre o canabidiol atingiu um primeiro pico, com as investigações centrando-se principalmente na sua 
interação com o delta9-THC e nos seus efeitos antiepiléptico e sedativo. As duas décadas seguintes apresentaram um menor nível de 
interesse e as propriedades terapêuticas potenciais do canabidiol investigadas foram, principalmente, as ansiolíticas, antipsicóticas e 
seus efeitos sobre as doenças motoras. Os últimos cinco anos têm demonstrado um notável aumento de publicações sobre o cana-
bidiol, principalmente estimulado pela descoberta dos seus efeitos anti-inflamatório, anti-oxidativo e neuroprotetor. Estes estudos têm 
sugerido uma vasta gama de possíveis efeitos terapêuticos da canabidiol em várias condições, incluindo doença de Parkinson, doença 
de Alzheimer, isquemia cerebral, diabetes, náusea, câncer, artrite reumatóide e outras doenças inflamatórias. Conclusão: Nos últimos 
45 anos, foi possível demonstrar uma vasta gama de efeitos farmacológicos do canabidiol, muitos dos quais são de grande interesse 
terapêutico, que ainda necessitam ser confirmados por estudos clínicos.
Descritores: Canabidiol; Cannabis; Canabinóides; História; Usos terapêuticos
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Introduction
In the tip of secreting hairs located mainly on female-plant flowers 
and, in a smaller amount, in the leaves of cannabis plant, there 
are resin glands that have a considerable amount of chemically 
related active compounds, called cannabinoids. In some varieties 
of cannabis the main cannabinoid is the psychoactive component 
of the plant, delta9-tetrahydrocannabinol (delta9-THC). Cannabis 
varieties typically bred for fiber are nearly always relatively low in 
delta9-THC, cannabidiol (CBD) being the predominant cannabinoid 
in these plants.1 
Although CBD was isolated from marijuana extract in 1940 
by Adams et al.,2 for almost 25 years no further work has been 
reported, except for a few early works about its isolation. Only in 
1963 its exact chemical structure was elucidated by Mechoulam 
and Shvo.3 Over the following few years Mechoulam’s group was 
responsible for the structure and stereochemistry determination 
of the main cannabinoids, which opened a new research field on 
pharmacological activity of cannabis constituents.4,5
The evolution of the number of publications on CBD since 1963, 
in comparison with publications on cannabis in general, is shown in 
Figure 1. Only a few pharmacological studies on CBD were reported 
before the early 1970’s, showing that CBD had no cannabis-like 
activity.6 The number of publications increased in this decade and 
reached a first peak around 1975. In this period, a Brazilian research 
group led by Carlini, gave an important contribution, especially 
about the interactions of delta9-THC with other cannabinoids, 
including CBD.7 Then, the number of publications declined and 
remained stabilized until a few years ago. The interest in studies 
about cannabis was renewed in the early 1990’s, by the description 
and cloning of specific receptors for the cannabinoids in the 
nervous system and the subsequent isolation of anandamide, an 
endogenous cannabinoid.8 Afterwards, the number of publications 
about cannabis has been continuously growing, but the reports on 
CBD remained stable until the early 2000’s. In the last five years 
there has been an explosive increase in publications on CBD, with 
the confirmation of a plethora of pharmacological effects, many of 
them with therapeutic potential.
There are some recent and very good reviews on CBD.9-12 As 
historical aspects have so far not been yet emphasized, the aim of 
the present review is to describe the development of this research 
field which transformed our view about CBD from an inactive 
cannabinoid to a drug with multiple actions. 
Inactive cannabinoid that interact with delta9-THC (1970’s)
The early pharmacological tests on isolated cannabinoids 
had evidenced that except for delta9-THC, no other major 
psychotomimetically active compounds were present in cannabis.13 
During this period, several reports attested that CBD was unable to 
mimic the effects of cannabis both in animals14 and in humans,15,16 
leading to the thought that it was an inactive cannabinoid.
This thought began to change with the observation that the 
activity in animals of several samples of cannabis differed widely, 
a fact which could not be attributed only to the different delta9-
THC contents of the samples.17,18 It was then hypothesized that 
other cannabinoids, among them CBD, could be interfering with 
the delta9-THC effects.
Many interactive studies between CBD and delta9-THC were 
accomplished by different groups, producing seemingly contradictory 
results both in animals,19-21 and in humans.22-24 Different schedules 
of drug administration used in these studies may help  explain the 
contradictions. It seems that CBD administered before delta9-THC 
potentiates the effects of the latter compound. However, concomitant 
use of both compounds suggests that CBD antagonizes delta9-THC 
effects.25-27 This difference could be explained by pharmacokinetic 
or pharmacodynamic interactions between the two cannabinoids.
CBD has been found to be a potent inhibitor of hepatic drug 
metabolism.28,29 Pre-treatment of mice with high doses of CBD 
causes an increase in delta9-THC level in the brain.30 Recently, 
evidence that CBD also inhibits the metabolic hydroxylation 
of delta9-THC in human volunteers31 has been obtained. This 
pharmacokinetic interaction could explain the increased effects of 
delta9-THC by CBD pretreatment. On the other hand, CBD is not 
able to change delta9-THC blood level with co-administration of 
both compounds in rats32 or humans volunteers.33 Therefore, it 
has been suggested that CBD can antagonize delta9-THC effects 
pharmacodynamically.34
Early evidence (1970’s) on CBD pharmacological activity
1. Antiepileptic action
The first pharmacological actions of CBD described were the 
antiepileptic and the sedative ones. In 1973, a Brazilian group 
reported that CBD was active in reducing or blocking convulsions 
produced in experimental animals by a variety of procedures,35,36 
which  was confirmed by another group one year later.37 At the 
end of that decade, the same Brazilian group has tested CBD as 
a treatment for intractable epilepsy in 16 grand- mal patients. 
Each patient received, in a double-blind procedure, 200 to 300 
mg daily of CBD or placebo for as long as four and a half months. 
Throughout the experiment, the patients did not stop taking the 
antiepileptic drugs prescribed before the experiment (which had 
not eliminated their seizures). Only one of the eight patients getting 
CBD showed no improvement, while among the patients who 
received the placebo, 1 improved and 7 remained unchanged.38 In a 
less successful study, no significant improvement in seizure 
frequency was observed among 12 epileptic patients who 
received 200-300 mg of cannabidiol per day, in addition to 
standard antiepileptic drugs.39 No further clinical trials with CBD 
have been published since then. Therefore, the clinical efficacy of 
CBD on epilepsy is still uncertain.
2. Sedative action
In the early 1970’s, suggestive evidence of a sedative action 
appeared, based on the observation that CBD reduced ambulation in 
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rats40 and, with higher doses, operant behavior in rats and pigeons.41 
Few years later, Monti42 reported sleep-inducing effects of CBD in 
rats, with an increase in total sleeping time, increment of slow-wave 
sleep (SWS) and decrease of SWS latency. In humans with insomnia, 
high doses of CBD (160 mg) increased sleep duration compared to 
placebo.43 Sedative effect was also observed in healthy volunteers 
with high CBD dose (600 mg).44 This effect of CBD may be biphasic, 
since in low doses (15 mg) the cannabinoid appears to have alerting 
properties in healthy volunteers, as it increases wakefulness during 
sleep and counteracts the residual sedative activity of 15 mg THC.45 
Previous reports of subjective feelings by healthy volunteers after 
CBD (1 mg/Kg) showed a significant increase in “clear minded” 
and “quick- witted” feelings, in contrast with THC (0.5 mg/Kg) that 
induced an increase in “muzzy”46 feelings. In agreement with the 
two last observations, intracerebroventricular administration of CBD 
in rats during the lights-on period increased wakefulness (W) and 
decreased rapid eye movement sleep (REMS), probably through 
increased dopamine release.47
CBD effects on anxiety, psychoses and movement disorders 
(1980’s and 1990’s) 
After the peak of reports on CBD in the 1970’s, the next two 
decades the publication rate remained stabilized, indicating a lower 
degree of interest on the study of therapeutic actions of CBD. The 
reports in this field were maintained mainly by Brazilian researchers 
investigating the anxiolytic and antipsychotic properties of CBD and 
by a few studies about its effects in motor diseases conducted by 
Consroe et al.48,49
1. Anxiolytic action
In 1974, an interactive study between CBD and THC, per os, 
in healthy volunteers, gave the first clue that CBD could act as an 
anxiolytic drug.22 This study showed that CBD (60 mg), added to 
delta9-THC (30 mg), changed the symptoms induced by delta9-
THC alone in such a way that the subjects receiving the mixture 
showed less anxiety and more pleasurable effects. In 1982, a study 
with appropriate rating scales confirmed that CBD (1 mg/kg), co-
administered with delta9-THC (0.5 mg/kg), significantly reduced 
anxiety indexes in healthy volunteers.46
The anxiolytic properties of CBD have been demonstrated by 
several pre-clinical studies that employed different paradigms such 
as the conditioned emotional response,50 the Vogel conflict test51 
and the elevated plus-maze.52,53 In the latter study,53 the effective 
doses of CBD ranged from 2.5 to 10 mg/kg, and the drug produced 
an inverted U-shaped dose-response curve, the higher doses being 
no longer effective. This could explain the negative results obtained 
with high doses of CBD (above 100 mg/kg) in a previous study 
employing the Geller-Seifter conflict test.54 A recent study showed 
that the anxiolytic effect of CBD in the Vogel test was not mediated 
by benzodiazepine receptors.55 
In order to evaluate a possible anxiolytic effect of CBD in humans, 
a double-blind study was conducted on healthy volunteers submitted 
to a simulation of the public speaking test. CBD (300 mg, po) was 
compared to ipsapirone (5 mg), diazepam (10 mg) or placebo. 
The results showed that both CBD and the two other anxiolytic 
compounds attenuated the anxiety induced by the test.56 The 
anxiolytic-like effect of CBD in healthy volunteers was also observed 
in a more recent double-blind study that investigated its effects on 
regional cerebral blood flow by single-photon emission computed 
tomography. Because the procedure itself can be interpreted as 
an anxiogenic situation, it allows the evaluation of anxiolytic drug 
action. CBD induced a clear anxiolytic effect and a pattern of cerebral 
activity compatible with an anxiolytic activity.57 Another study, 
using functional magnetic resonance imaging (fMRI) to investigate 
the neurophysiologic basis of the effects of cannabis on human 
anxiety, showed that CBD affected activation when subjects were 
processing intensely fearful stimuli, attenuating responses in the 
amygdala and cingulate cortex. The suppression of the amygdalar 
response was correlated to the drug effect of reducing fluctuations 
of skin conductance.58 Therefore, similar to the data obtained in 
animal models, results from studies in healthy volunteers strongly 
suggest an anxiolytic action of CBD. 
2. Antipsychotic action
The first evidence that CBD could have antipsychotic effects 
was obtained in the interactive study of CBD and delta9-
THC in healthy volunteers published in 1982.46 This study 
demonstrated that CBD could inhibit THC-induced subjective 
changes that resembled symptoms of psychotic diseases such as: 
disconnected thought, perceptual disturbance, depersonalization 
and resistance to communication. In the same year, it was 
observed that patients admitted to a psychiatric hospital in South 
Africa, after the use of a variety of cannabis virtually devoid 
of CBD, showed much higher frequency of acute psychotic 
episodes than in other countries.59 These lines of evidence 
led to several investigations of a possible antipsychotic 
 action of CBD.
As a first step to investigate antipsychotic-like properties of CBD 
in animal models, the drug was compared to haloperidol in rats.60 
Both drugs reduced the apomorphine-induced stereotyped behavior 
(such as sniffing and biting), in a dose-related manner. Even though 
these drugs also increased the plasma level of prolactine, CBD 
needs higher doses (120 and 240 mg/kg) to show such an effect. 
Moreover, contrary to haloperidol, CBD did not induce catalepsy, 
even at doses as high as 480 mg/kg. These results suggest that CBD 
may exhibit a profile similar to atypical antipsychotic drugs. Recently, 
a study tested CBD effects both in dopamine-based and glutamate-
based models predictive of antipsychotic activity in mice.61 In this 
study CBD was compared to haloperidol and clozapine, an atypical 
antipsychotic drug. CBD inhibited the hyperlocomotion induced 
by amphetamine in a dose-related manner, in agreement with 
the data obtained with another dopamine-based model, and also 
attenuated the hyperlocomotion induced by ketamine, extending its 
antipsychotic-like action to a glutamate-based model. As expected, 
while both haloperidol and clozapine inhibited hyperlocomotion, 
only haloperidol induced catalepsy within the dose range used. 
Therefore, similar to clozapine, CBD did not induce catalepsy 
with doses that inhibited hyperlocomotion. Strengthening these 
results, CBD reversed the disruption of prepulse inhibition (PPI) 
of the startle response in mice caused by MK-801, a glutamate 
receptor antagonist, as did clozapine, further supporting the idea 
that this compound may act as an atypical antipsychotic drug.62 
Consistent with the behavioral data, both CBD and clozapine, 
but not haloperidol, induced Fos immunoreactivity (Fos) in the 
prefrontal cortex, while only haloperidol increased Fos in the dorsal 
striatum.63,64
Even in human models of psychotic symptoms induced in 
healthy volunteers, the antipsychotic-like activity of CBD can be 
demonstrated. In the perception of binocular depth inversion, used to 
evaluate the antipsychotic effects of new drugs,65 the impairment of 
History of research on cannabidiol
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the perception of illusory image induced by nabilone was attenuated 
by CBD, suggesting an antipsychotic-like effect of this compound.66 
Another model used to evaluate antipsychotic-like activity of drugs in 
healthy volunteers is the administration of sub-anesthetic doses of 
ketamine that induce a psychotic reaction mimicking both positive 
and negative symptoms of schizophrenia.67 A double-blind crossover 
procedure using this model was performed to compare the effects 
of CBD (600 mg) and placebo in nine healthy volunteers.68 CBD 
attenuated the effects of ketamine on the depersonalization factor 
of a dissociative rating scale, further reinforcing the antipsychotic-
like properties of CBD.
The therapeutic use of CBD in psychotic patients was tested for 
the first time in 1995. In a case study, a schizophrenic patient, 
who presented serious side effects after treatment with conventional 
antipsychotics, received oral doses of CBD (reaching 1500 mg/day) 
for 4 weeks.69 A significant improvement was observed during CBD 
treatment, while a worsening was observed when the administration 
was interrupted. More recently, CBD was administered to three 
schizophrenic patients who had not responded to typical antipsychotic 
drugs.70 A partial improvement was observed in one patient, but 
only slight or no improvement in the other two, thus suggesting that 
CBD has little effect in patients resistant to typical antipsychotics. 
Confirming the suggestion of case-studies, a preliminary report from 
a 4-week double-blind controlled clinical trial, using an adequate 
number of patients and comparing the effects of CBD with amisulpride 
in acute schizophrenic and schizophreniform psychosis, showed 
that CBD significantly reduced acute psychotic symptoms after 2 
and 4 weeks of treatment when compared to baseline. In this trial, 
CBD did not differ from amisulpride except for a lower incidence 
of side effects.71 In conclusion, clinical studies suggest that CBD 
is an effective, safe and well-tolerated alternative treatment for 
schizophrenic patients.
3. Action on movement disorders
The possible therapeutic effect of CBD on movement disorders 
came from anecdotal accounts and preliminary reports of open trials, 
in the middle 1980’s. CBD (100 to 600 mg/day) had antidystonic 
effects in humans when administered along with standard medication 
to five patients with dystonia, in an open study.48 In Huntington’s 
disease (HD), the effectiveness of CBD was investigated with a 
small number of patients (four) and a non-blinded design, showing 
some beneficial effects of CBD.72 However, the latter finding was not 
confirmed by a study comparing the effects of oral CBD (10 mg/kg/
day for 6 weeks) with placebo under a double-blind, randomized 
cross-over design. In this study, CBD at an average daily dose of 
about 700 mg/day was neither symptomatically effective nor toxic 
in neuroleptic-free patients with HD.49 
Afterwards, this field of research was apparently abandoned until 
recently, when CBD’s neuroprotective effects began to be reported 
in animal models of Parkinson’s disease. 
CBD as a drug with a wide spectrum of action (2000’s)
The interest in studies about cannabis was renewed in the early 
1990’s, with the description and cloning of specific receptors for 
the cannabinoids (CB1 and CB2) in the nervous system and the 
subsequent isolation of anandamide, an endogenous cannabinoid.73 
After that, the number of publications about cannabis has been 
continuously growing, attesting the great interest in research 
involving the herb. However, the number of studies on CBD has 
increased only in the last five years (Figure 1), mainly stimulated 
by discoveries of the anti-inflammatory, anti-oxidative and 
neuroprotective actions of CBD.
1. Anti-oxidative and neuroprotective actions
In the late 1990’s, it was demonstrated that CBD reduced 
glutamate toxicity mediated by N-methyl-D-aspartate receptors 
(NMDAr), 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl) propionic 
acid receptors (AMPA) or kainate receptors. The neuroprotection 
observed with cannabidiol was not affected by a cannabinoid receptor 
antagonist, indicating it is cannabinoid-receptor independent.74 
Previous studies had shown that glutamate toxicity may be prevented 
by antioxidants. In line with this, it was demonstrated that CBD can 
reduce hydroperoxide-induced oxidative damage as well as or better 
than other antioxidants. CBD was more protective against glutamate 
neurotoxicity than either ascorbate or a-tocopherol, indicating that 
this drug is a potent antioxidant.74
The anti-oxidative action of CBD can be responsible for the 
neuroprotection reported in animal models of Parkinson’s disease 
(PD). Daily administration of CBD during 2 weeks may produce 
a significant waning in the magnitude of toxic effects caused by a 
unilateral injection of 6-hydroxydopamine into the medial forebrain 
bundle,75 probably due to receptor-independent actions. In this 
model of PD, CBD led to an up-regulation of mRNA levels of Cu/Zn-
superoxide dismutase, a key enzyme in endogenous defense against 
oxidative stress. The conclusion was that the antioxidant properties 
of CBD can provide neuroprotection against the progressive 
degeneration of nigrostriatal dopaminergic neurons that occur in 
PD.76 This is reinforced by the observation that CBD reduced the 
striatal atrophy caused by 3-nitropropionic acid, in vivo, through 
mechanisms independent of the activation of cannabinoid, vanilloid 
TRPV1 and adenosine A2A receptors.
77 The neuroprotective action 
of CBD in the human basal ganglia was suggested by the strong 
positive correlation of N-acetylaspartate/total creatine ratio and CBD 
in the putamen/globus pallidum found in recreational cannabis 
users. This could reflect an enhancement of neuronal and axonal 
integrity in these regions by CBD.78 Considering the relevance of 
these preclinical data and the possible antipsychotic effect of CBD, 
a recently study evaluated, for the first time, the efficacy, tolerability 
and safety of CBD in PD patients with psychotic symptoms.79 In an 
open-label pilot study, six consecutive outpatients with the diagnosis 
of PD and who also had psychosis for at least 3 months, have 
received a flexible-dose regimen of CBD administration (starting 
with an oral dose of 150 mg/day) for four weeks, in addition to their 
usual therapy. The psychotic symptoms significantly decreased along 
the CBD treatment, and the scale used to follow up the PD course 
exhibited a significant decrease of the total score. These preliminary 
data suggest that CBD may have a beneficial action in PD.79
The possible neuroprotective actions of CBD highlight the 
importance of studies on the therapeutic potential of this compound 
in Alzheimer’s disease (AD). AD is widely associated with oxidative 
stress due in part, to the membrane action of beta-amyloid peptide 
(beta-A) aggregates. A marked reduction in the cell survival was 
observed following exposure of cultured rat pheochromocytoma 
PC12 cells to beta-A peptide. Treatment of the cells with CBD prior to 
beta-A exposure significantly elevated the cell survival, probably by 
a combination of neuroprotective, anti-oxidative and anti-apoptotic 
actions against beta-A toxicity. In addition, CBD inhibited caspase 
3 generation from its inactive precursor, pro-caspase 3, an effect 
that is involved in the signaling pathway for this neuroprotection.80 
In the search for the molecular mechanism of this CBD-induced 
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neuroprotective action it was reported that CBD inhibits 
hyperphosphorylation of tau protein in beta-A-stimulated PC12 
neuronal cells, which is one of the most representative hallmarks 
of AD.81 A possible anti-inflammatory action may be involved in 
this CBD effect, since CBD inhibited both nitrite production and 
nitric oxide synthase (iNOS) protein expression induced by beta-A.82 
These results of in vitro studies were confirmed in vivo with a mouse 
model of AD-related neuroinflammation. Mice were inoculated 
with human beta-A into the right dorsal hippocampus, and treated 
daily with vehicle or CBD (2.5 or 10 mg kg, i.p.) for 7 days. In 
contrast to vehicle, CBD dose-dependent significantly inhibited 
mRNA for glial fibrillary acidic protein and the protein expression 
in beta-A injected animals. Moreover, under the same experimental 
conditions, CBD impaired iNOS and IL-1beta protein expression, 
and the related NO and IL-1beta release.83 The possibility of CBD 
inhibiting beta-A-induced neurodegeneration is very promising to 
AD prevention.
Recently it has been suggested that CBD may protect neurons 
against the multiple molecular and cellular factors involved in 
the different steps of the neurodegenerative process, which takes 
place during prion infection.84 Prion diseases are transmissible 
neurodegenerative disorders characterized by the accumulation 
in the CNS of the protease-resistant prion protein, a structurally 
misfolded isoform of its physiological counterpart.84
2. Anti-inflammatory action
In 2000, a few previous reports showing that CBD can 
modulate tumor necrosis factor in vitro and suppress chemokine 
production by a human B cell,85-87 motivated  the study of CBD 
as a therapeutic agent in collagen-induced arthritis, a model for 
rheumatoid arthritis.88 This model is based on immunizing mice 
with type-II collagen. CBD, administered i.p. or orally, has blocked 
the progression of arthritis. Dose-dependency was shown by a 
bell-shaped curve, with an optimal effect at 5 mg/kg per day (i.p.), 
or at 25 mg/kg per day (orally). In addition, CBD has suppressed 
T cell responses and has decreased the release of bioactive tumor 
necrosis factor (TNF) from synovial cells isolated from arthritic knee 
joints of treated mice. Data of this study suggest that the antiarthritic 
effect of CBD is due to a combination of immunosuppressive and 
anti-inflammatory actions.10,12 A CBD anti-inflammatory effect was 
observed in acute inflammation induced by intraplantar injection of 
0.1 ml carrageenan in rats.89 Oral CBD (5-40 mg/kg) once a day 
for 3 days after the onset of acute inflammation had a beneficial 
action on edema and hyperalgesia. CBD also proved effective in 
chronic neuropathic (sciatic nerve chronic constriction) painful 
states in rats, reducing hyperalgesia to mechanical stimuli. This 
effect was prevented by the vanilloid antagonist capsazepine, 
but not by cannabinoid receptor antagonists.90 In these models 
of inflammation, decreases in prostaglandin E2 (PGE2) plasma 
levels, tissue cyclooxygenase (COX) activity and production of 
nitric oxide (NO)89,90 have been observed. The suppressive effects 
of CBD on cellular immune responses and on the production of 
pro-inflammatory mediators may indicate its usefulness in several 
inflammatory diseases.
3. Action on ischemia
The anti-oxidative and anti-inflammatory properties of CBD 
have led to the research of its possible activity in preventing 
damage caused by cerebral ischemia. CBD (1.25-20 mg/kg) was 
administered to freely-moving gerbils 5 min after bilateral carotid-
artery occlusion for 10 minutes. Seven days after the ischemia, 
CBD antagonized electroencephalographic flattening, showing 
a dose-dependent bell-shaped curve. The best neuroprotective 
effect was observed at 5 mg/kg. Histological examination showed 
the complete survival of CA1 neurons in CBD-treated gerbils.91 
A similar effect has been reported by another research group in 
mice, after middle cerebral artery occlusion; the neuroprotective 
action of CBD being unaffected by CB1 receptor blockade.
92 The 
same research group has verified that this effect was inhibited by 
WAY100135, a serotonin 5-hydroxytriptamine 1A (5-HT1A) receptor 
antagonist, but not by capsazepine, a vanilloid receptor antagonist, 
suggesting that the neuroprotective effect of CBD may be due to 
the increase in cerebral blood flow mediated by the serotonergic 
5-HT1A receptor.
93 Experimental evidence has suggested that beyond 
this action on the 5-HT1A receptor, the protective effect of CBD on 
ischemic injury is also secondary to its anti-inflammatory action.94 
In another study, the same research group reported that, while 
repeated treatment with delta9-THC leads to the development of 
tolerance for this neuroprotective effect, this phenomenon is not 
observed with CBD.95
CBD has been studied for ischemic heart diseases in rats.96 The 
left anterior descending coronary artery was transiently obstructed 
for 30 min, and the rats were treated for 7 days with CBD (5 mg/kg, 
ip) or vehicle. Cardiac function was studied by echocardiography 
and showed preservation of shortening fraction in CBD-treated 
animals. Infarct size was reduced by 66% in CBD-treated animals 
and this effect was associated with reduction of myocardial 
inflammation and reduction of IL-6 levels. In isolated hearts, no 
significant difference was detected between rats that received 
CBD or vehicle regarding: infarct size, left ventricular developed 
pressures during ischemia and reperfusion, or coronary flow. This 
study shows that CBD induces a substantial cardioprotective effect, 
but only in vivo.
4. Action on diabetes
The potent anti-inflammatory effect of CBD, with reduction of 
cytokines production (IFN-γ and TNF-α) and inhibition of T cell 
proliferation observed in experimental arthritis,88 led to investigation 
of the possible CBD effects on others autoimmune diseases.12 Type 
1 diabetes mellitus (insulin-dependent) is an autoimmune disease 
that results in the destruction of insulin-producing pancreatic β 
cells. The initial lesion of insulin-dependent diabetes mellitus is an 
inflammation of the islands of Langerhans, during which leukocytes, 
lymphocytes in particular, surround and infiltrate the islets. That way 
Mechoulam’s group investigated CBD action on non-obese diabetic 
(NOD) mice. They found that CBD treatment of NOD mice before 
the development of the disease reduced its incidence from 86% 
in the non-treated control mice to 30% in CBD-treated mice. CBD 
treatment also resulted in significant reduction of plasma levels 
of the pro-inflammatory cytokines, IFN-γ and TNF-α. Histological 
examination of the pancreatic islets of CBD-treated mice revealed 
significant reduction of the inflammation.97 It was also observed 
that administration of CBD to 11-14 week old female NOD mice, 
which were either in a latent diabetes stage or had initial symptoms 
of diabetes, ameliorated the manifestations of the disease. In 
addition, the level of the pro-inflammatory cytokine IL-12 produced 
by splenocytes was significantly reduced, whereas the level of 
the anti-inflammatory IL-10 was significantly elevated after CBD 
treatment.98 This data have suggested that CBD can possibly be used 
as a therapeutic agent for the treatment of type 1 diabetes.
History of research on cannabidiol
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CBD has also been proven useful for possible complications of 
diabetes. The majority of diabetic complications are associated with 
pathophysiological alterations in the vasculature. Microvascular 
complications involve retinopathy and nephropathy while the 
atherosclerosis is the most common macrovascular complication of 
diabetes. The protective effects of CBD were studied in experimental 
diabetes induced by streptozotocin in rats. CBD treatment prevented 
retinal cell death and vascular hyperpermeability in the diabetic retina. 
In addition, it significantly reduced oxidative stress, decreased the 
levels of TNF-α, vascular endothelial growth factor, and intercellular 
adhesion-molecule.99 It has also been suggested that CBD has 
significant therapeutic benefits against other diabetic complications 
and atherosclerosis, since it attenuated several effects of high glucose, 
including the disruption of the endothelial function.100
 
5. Antiemetic action
The treatment of nausea and vomiting associated with 
chemotherapy was one of the first therapeutic uses of cannabis 
and cannabinoids that has been evaluated with clinical trials. In 
the mid 1970’s, a clinical trial indicated that delta9-THC was 
effective as an anti-nausea agent in patients receiving cancer 
chemotherapy.101 In 1990, a survey of the members of the 
American Society of Clinical Oncology found that more than 44% 
of the respondents reported that they had already recommended 
the use of marijuana for the control of emesis to at least one cancer 
chemotherapy patient.102
Although the anti-emetic action has been associated to delta9-THC, 
many users claim that marijuana suppresses nausea more effectively 
than oral delta9-THC.103 These observations led a Canadian group 
to investigate whether CBD can suppress nausea in the conditioned 
rejection model in rats. The association between a flavor and an 
emetic drug results in altered affective reactions, called conditioned 
rejection reactions, which reflect nausea.10 In this model, rats 
were injected with a low dose (5 mg/kg i.p.) of CBD, a synthetic 
dimethylheptyl homolog of CBD, or vehicle 30 min prior to a pairing 
of saccharin solution and lithium chloride (20 ml/kg of 0.15 M 
LiCl) or saline. The rejection reactions (gapes, chin rubs and paw 
treads) that were elicited by lithium chloride and by a flavor paired 
with lithium chloride were suppressed by CBD and its synthetic 
dimethylheptyl homolog.104 Since rats are incapable of vomiting, a 
better model for vomiting was found with a mouse species (Suncus 
murinus), which both vomits and expresses nausea.12 These animals 
were injected with vehicle or one of two cannabinoids, THC (1-20 
mg/kg) or CBD (2.5-40 mg/kg), 10 min prior to an injection of 
LiCl (390 mg/kg of 0.15 M) and were then observed for 45 min. 
delta9-THC produced a dose-dependent suppression of Li-induced 
vomiting while CBD produced a biphasic effect, having lower doses 
produced suppression and higher doses produced enhancement 
of Li-induced vomiting. The suppression of Li-induced vomiting by 
delta9-THC, but not by CBD, was reversed by SR-141716, a CB1 
antagonist, suggesting that both cannabinoids are effective treatments 
for Li-induced vomiting, however, only delta9-THC acts through the 
CB1 receptor.
105 CBD was effective also in the conditioned retching 
reaction, which is a model of anticipatory nausea. Following three 
pairings of a novel distinctive contextual cue with the emetic effects of 
an injection of lithium chloride, the context acquired the potential to 
elicit conditioned retching in the absence of the toxin. The expression 
of this conditioned retching reaction was completely suppressed by 
CBD and delta9-THC, but not by ondansetron, a 5-HT3 antagonist 
that interferes with acute vomiting in this species.106 A similar effect 
of CBD on anticipatory nausea was observed with a rat model of 
nausea (conditioned gaping).107 These results support anecdotal 
claims that marijuana may suppress the expression of anticipatory 
nausea experienced by chemotherapy patients, resistant to current 
anti-nausea treatments.
6. Anticancer action
In the mid 1970’s, several cannabinoids, including CBD, were 
studied in cancer cells and the results observed with CBD were 
not promising. However, these experiments were performed with 
extremely high doses (e.g., 200 mg/kg) and it is unlikely that these 
observations are relevant to the usual doses of CBD.12
In 2000, the interest in CBD as a potential anticancer drug was 
renewed with an investigation of its effect on glioma cells. In this 
study, CBD produced a modest reduction in the cell viability of C6 
rat glioma cells, only evident after 6 days of incubation with the 
drug and only in a serum-free condition.108 A further study has 
demonstrated that CBD, in vitro, caused a concentration-related 
inhibition of the human glioma cell viability that was already evident 
24 h after the CBD exposure and significantly inhibited the growth 
of subcutaneously implanted human glioma cells in nude mice. The 
authors also showed for the first time that the antiproliferative effect 
of CBD was correlated to induction of apoptosis, as determined by 
cytofluorimetric analysis and single-strand DNA staining, which was 
not reverted by cannabinoid and vanilloid receptor antagonists.109 
CBD also caused apoptosis in human myeloblastic leukemia cells.110 
In addition, CBD inhibits the migration of U87 human glioma cells 
in vitro and this effect was also not antagonized by either selective 
CB1 or CB2 receptor antagonists.
111 A study of the effect of different 
cannabinoids on eight tumor cell lines, in vitro, has clearly indicated 
that, of the five natural compounds tested, CBD was the most potent 
inhibitor of cancer cell growth. In this study, two different tumor cell 
lines transplanted to hairless mice were half as big as those of the 
untreated group, and both breast- and lung-cancer cells injected to 
paws showed approximately three times less metastatic invasion.112 
An inhibitor of basic helix-loop-helix transcription factors (Id1) has 
recently been shown to be a key regulator of the metastatic potential 
of breast and additional cancers. CBD could down-regulate the 
Id-1 expression in aggressive human breast cancer cells, and the 
concentrations effective at inhibiting Id-1 expression correlated 
with those used to inhibit the proliferative and invasive phenotype 
of breast cancer cells.113
The precise mechanisms underlying CBD effects on apoptosis 
and tumor growth are not clear, and have recently been discussed 
in a review by Mechoulam.12
CBD: a drug with multiple mechanisms of action
The plethora of CBD effects described above can be explained by 
its multiple mechanisms of action. The description and cloning of 
specific receptors for the cannabinoids in the nervous system have 
been a great contribution to the understanding of the mechanism of 
actions of cannabinoids. However, in contrast to delta9-THC, CBD 
has little affinity to CB1 and CB2 receptors.
114
1. Actions on the cannabinoid system
In spite of its low affinity for CB1 and CB2 receptors, experimental 
evidence has shown that CBD is capable of antagonizing CB11/
CB2 receptor agonists at reasonably low concentrations.
115 This 
unexpected effect of CBD raises the possibility that this antagonism 
is non-competitive in nature, a hypothesis that has been discussed 
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by Pertwee.116 Recently, the cloning and protein sequence of the 
human, mouse and rat new cannabinoid receptor (GPR55) that can 
be activated by the established CB1/CB2 receptor agonists, such as 
delta9-THC and endogenous cannabinoids, has been described. 
The activation of the GPR55 receptor is antagonized by CBD at a 
concentration that is below any concentration at which it displaces 
agonists from CB1 or CB2 receptors.
117 Other actions of CBD on the 
cannabinoid system are the blockade of anandamide uptake and 
the inhibition of its enzymatic hydrolysis.118
2. Action on the vanilloid receptor type 1
CBD stimulated vanilloid receptors (VR1) with EC50 = 3.2 ± 
3.5 mM and with a maximal effect similar in efficacy to that of 
capsaicin, the natural agonists of this receptor.118 Although VR1 
is involved in inflammatory hyperalgesia, the stimulation of this 
receptor by capsaicin and some of its analogues leads to rapid 
desensitization, with subsequent paradoxical analgesic and 
anti-inflammatory effects. CBD desensitized VR1 to the action of 
capsaicin, thus opening the possibility that this cannabinoid exerts 
an anti-inflammatory action in part by desensitization of sensory 
nociceptors.118
3. Action on the5-HT1A receptor
CBD displaces the agonist [3H]8-OHDPAT from the cloned 
human 5-HT1A receptor in a concentration-dependent manner. In 
signal-transduction studies, CBD acts as an agonist at the human 
5-HT1A receptor.
119 This CBD action is probably involved in the 
protective effect of CBD on ischemia93 and in its anxiolytic-like 
effects.120
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